Institutional investors purchased a net $2.2 million shares of UMRX during the quarter ended March 2019. This may signal that the smart money is gaining interest in this company as the 13.91% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
RENAISSANCE TECHNOLOGIES LLC Bought 341.5 Thousand shares of Unum Therapeutics Inc
CHI ADVISORS LLC Bought 150.0 Thousand shares of Unum Therapeutics Inc
ANSON FUNDS MANAGEMENT LP Bought 135.2 Thousand shares of Unum Therapeutics Inc